FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1582968384> ?p ?o ?g. }

• W1582968384 endingPage "8" @default.
• W1582968384 startingPage "2344" @default.
• W1582968384 abstract "Bryostatin-1, a macrocyclic lactone, appears to elicit a wide range of biological responses including modulation of protein kinase C (PKC). PKC, one of the major elements in the signal transduction pathway, is involved in the regulation of cell growth, differentiation, gene expression, and tumor promotion. Because of the potential for a unique mechanism of interaction with tumorgenesis, a Phase I trial of bryostatin-1 was performed in children with solid tumors to: (a) establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); (b) establish the pharmacokinetic profile in children; and (c) document any evidence of antitumor activity. A 1-h infusion of bryostatin-1 in a PET formulation (60% polyethylene glycol 400, 30% ethanol, and 10% Tween 80) was administered weekly for 3 weeks to 22 children (age range, 2-21 years) with malignant solid tumors refractory to conventional therapy. Doses ranged from 20 to 57 microg/m2/ dose. Pharmacokinetics were performed in at least three patients per dose level. The first course was used to determine the DLT and MTD. Twenty-two patients on five dose levels were evaluable for toxicities. At the 57 microg/m2/dose level dose-limiting myalgia (grade 3) was observed in three patients; two of those patients also experienced photophobia or eye pain, and one experienced headache. Symptoms occurred in all patients within 24-72 h after the second dose of bryostatin-1 with resolution within 1 week of onset. Other observed toxicities (grades 1 and 2) included elevation in liver transaminases, thrombocytopenia, fever, and flu-like symptoms. The bryostatin-1 infusion was typically well tolerated. Although stable disease was noted in several patients, no complete or partial responses were observed. The recommended Phase II dose of bryostatin-1 administered as a 1-h infusion weekly for 3 of every 4 weeks to children with solid tumors is 44 microg/m2/dose. Myalgia, photophobia, or eye pain, as well as headache, were found to be dose limiting." @default.
• W1582968384 created "2016-06-24" @default.
• W1582968384 creator A5001314462 @default.
• W1582968384 creator A5025699758 @default.
• W1582968384 creator A5028088882 @default.
• W1582968384 creator A5035201571 @default.
• W1582968384 creator A5054825742 @default.
• W1582968384 creator A5067299217 @default.
• W1582968384 creator A5074225380 @default.
• W1582968384 creator A5081765963 @default.
• W1582968384 creator A5086393033 @default.
• W1582968384 date "1999-09-01" @default.
• W1582968384 modified "2023-09-23" @default.
• W1582968384 title "A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study." @default.
• W1582968384 cites W1480069833 @default.
• W1582968384 cites W1546234190 @default.
• W1582968384 cites W1579942173 @default.
• W1582968384 cites W1937458778 @default.
• W1582968384 cites W2007069751 @default.
• W1582968384 cites W2020515357 @default.
• W1582968384 cites W2027334353 @default.
• W1582968384 cites W2048193593 @default.
• W1582968384 cites W2050291163 @default.
• W1582968384 cites W2056520991 @default.
• W1582968384 cites W2114312013 @default.
• W1582968384 cites W2116403966 @default.
• W1582968384 cites W2128644586 @default.
• W1582968384 cites W2128796524 @default.
• W1582968384 cites W2137637658 @default.
• W1582968384 cites W2140879800 @default.
• W1582968384 cites W2148906835 @default.
• W1582968384 cites W2166030036 @default.
• W1582968384 cites W218420279 @default.
• W1582968384 cites W2275165869 @default.
• W1582968384 cites W3005434895 @default.
• W1582968384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10499603" @default.
• W1582968384 hasPublicationYear "1999" @default.
• W1582968384 type Work @default.
• W1582968384 sameAs 1582968384 @default.
• W1582968384 citedByCount "15" @default.
• W1582968384 countsByYear W15829683842015 @default.
• W1582968384 countsByYear W15829683842017 @default.
• W1582968384 crossrefType "journal-article" @default.
• W1582968384 hasAuthorship W1582968384A5001314462 @default.
• W1582968384 hasAuthorship W1582968384A5025699758 @default.
• W1582968384 hasAuthorship W1582968384A5028088882 @default.
• W1582968384 hasAuthorship W1582968384A5035201571 @default.
• W1582968384 hasAuthorship W1582968384A5054825742 @default.
• W1582968384 hasAuthorship W1582968384A5067299217 @default.
• W1582968384 hasAuthorship W1582968384A5074225380 @default.
• W1582968384 hasAuthorship W1582968384A5081765963 @default.
• W1582968384 hasAuthorship W1582968384A5086393033 @default.
• W1582968384 hasConcept C112705442 @default.
• W1582968384 hasConcept C126322002 @default.
• W1582968384 hasConcept C142424586 @default.
• W1582968384 hasConcept C143998085 @default.
• W1582968384 hasConcept C170493617 @default.
• W1582968384 hasConcept C2778616394 @default.
• W1582968384 hasConcept C2910806222 @default.
• W1582968384 hasConcept C29730261 @default.
• W1582968384 hasConcept C71924100 @default.
• W1582968384 hasConcept C86803240 @default.
• W1582968384 hasConcept C87355193 @default.
• W1582968384 hasConcept C88045685 @default.
• W1582968384 hasConcept C90924648 @default.
• W1582968384 hasConcept C98274493 @default.
• W1582968384 hasConceptScore W1582968384C112705442 @default.
• W1582968384 hasConceptScore W1582968384C126322002 @default.
• W1582968384 hasConceptScore W1582968384C142424586 @default.
• W1582968384 hasConceptScore W1582968384C143998085 @default.
• W1582968384 hasConceptScore W1582968384C170493617 @default.
• W1582968384 hasConceptScore W1582968384C2778616394 @default.
• W1582968384 hasConceptScore W1582968384C2910806222 @default.
• W1582968384 hasConceptScore W1582968384C29730261 @default.
• W1582968384 hasConceptScore W1582968384C71924100 @default.
• W1582968384 hasConceptScore W1582968384C86803240 @default.
• W1582968384 hasConceptScore W1582968384C87355193 @default.
• W1582968384 hasConceptScore W1582968384C88045685 @default.
• W1582968384 hasConceptScore W1582968384C90924648 @default.
• W1582968384 hasConceptScore W1582968384C98274493 @default.
• W1582968384 hasIssue "9" @default.
• W1582968384 hasLocation W15829683841 @default.
• W1582968384 hasOpenAccess W1582968384 @default.
• W1582968384 hasPrimaryLocation W15829683841 @default.
• W1582968384 hasRelatedWork W1975762038 @default.
• W1582968384 hasRelatedWork W1979719945 @default.
• W1582968384 hasRelatedWork W2009476463 @default.
• W1582968384 hasRelatedWork W2083116469 @default.
• W1582968384 hasRelatedWork W2130207513 @default.
• W1582968384 hasRelatedWork W2774225352 @default.
• W1582968384 hasRelatedWork W2897816537 @default.
• W1582968384 hasRelatedWork W3167945921 @default.
• W1582968384 hasRelatedWork W4214585610 @default.
• W1582968384 hasRelatedWork W2164166808 @default.
• W1582968384 hasVolume "5" @default.
• W1582968384 isParatext "false" @default.
• W1582968384 isRetracted "false" @default.
• W1582968384 magId "1582968384" @default.

• next